Physiological experiments in affected individuals highlighted the possibility that sulphonylureas, used in T2D to bind and close the KATP channel, could be used as a targeted treatment option in KCNJ11 PNDM. The gene discussed is KCNJ11; the disease is type 2 diabetes mellitus.